Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 9—September 2025

Research

Differences in Lyme Disease Diagnosis among Medicaid and Medicare Beneficiaries, United States, 2016–2021

L. Hannah GouldComments to Author , Sarah J. Willis, Christopher G. Prener, Stephanie A. Duench, Holly Yu, Luis Jodar, Jennifer C. Moïsi, and James H. Stark
Author affiliation: Global Vaccines Medical Affairs, Pfizer, Inc., New York, New York, USA (L.H. Gould); Global Vaccines Medical Affairs, Pfizer, Inc., Cambridge, Massachusetts, USA (S.J. Willis, J.H. Stark); RWE Platforms and Partnerships, Pfizer, Inc., New York (C.G. Prener); US Medical Affairs, Vaccines and Anti-infectives, Pfizer, Inc., Collegeville, Pennsylvania, USA (S.A. Duench); Global HTA, Value & Evidence Vaccines, Pfizer, Inc., Collegeville (H. Yu); Global Vaccines Medical Affairs, Pfizer, Inc., Collegeville (L. Jodar); Global Vaccines Medical Affairs, Inc., Pfizer, Paris, France (J.C. Moïsi)

Main Article

Table 1

Number of cases and incidence in a study of differences in Lyme disease diagnosis among Medicaid and Medicare beneficiaries, United States, 2016–2021*

Group Total no. (%) cases† Localized Lyme disease
Disseminated Lyme disease
No. cases Person-years Incidence‡ No. cases Person-years Incidence‡
Medicaid, age <18 y 33,776 27,165 37,110,817 73.3 5,798 27,058,337 15.7
White 29,405 (87.1) 24,093 17,461,207 138.1 4,576 17,412,994 26.3
Black, African American 1,244 (3.7) 744 9,611,964 7.8 483 9,611,379 5.0
Asian, Pacific Islander 741 (2.2) 551 2,783,663 19.8 181 2,782,940 6.5
Hispanic 2,063 (6.1) 1,526 6,833,641 22.4 495 6,831,111 7.3
Native American 208 (0.6) 159 268,217 59.3 44 267,950 16.4
Other
115 (0.3)
92
152,126
60.5

19
151,963
12.5
Medicaid, age >19 y 30,935 23,663 25,536,958 92.7 5,380 25,496,013 21.1
White 26,298 (85.0) 20,456 13,156,621 155.6 4,214 13,120,278 32.1
Black, African American 1,461 (4.7) 978 6,188,543 15.8 408 6,187,289 6.6
Asian, Pacific Islander 1,082 (3.5) 813 2,745,246 29.6 212 2,743,918 7.7
Hispanic 1,867 (6.0) 1,253 3,235,335 38.8 500 3,233,589 15.5
Native American 191 (0.6) 133 168,295 79.1 40 168,080 23.8
Other
36 (0.1)







Medicare, age <65 y 12,911 8,204 6,933,720 118.4 3,293 6,923,326 47.6
White 11,845 (91.7) 7,581 5,149,098 147.3 2,930 5,139,283 57.1
Black, African American 513 (4.0) 284 1,267,371 22.4 205 1,267,135 16.2
Asian, Pacific Islander 72 (0.6) 50 105,505 47.4 16 105,440 15.2
Hispanic 293 (2.3) 181 284,434 63.7 84 284,264 29.6
Native American 53 (0.4) 32 32,348 99.0 14 32,306 43.4
Other
135 (1.0)
76
94,964
80.1

44
94,897
46.4
Medicare, age >65 y 90,913 65,298 31,199,802 209.4 16,938 31,087,605 54.5
White 87,831 (96.6) 63,252 27,353,152 231.4 16,201 27,243,943 59.5
Black, African American 1,172 (1.3) 753 2,299,786 32.8 324 2,298,791 14.1
Asian, Pacific Islander 591 (0.7) 410 649,660 63.2 141 649,082 21.7
Hispanic 283 (0.3) 183 357,614 51.2 76 357,380 21.3
Native American 64 (0.1) 45 30,197 149.1 14 30,127 46.5
Other 872 (1.1) 655 509,397 128.7 182 508,283 35.8

*–, sample size too small to calculate rate. †Total cases include all cases of Lyme disease identified during the study period. For incidence rate calculations, we included only the first case during the study period for beneficiaries with subsequent Lyme disease diagnoses. ‡Incidence rate was calculated across the entire study period among all persons who had <183 days of continuous enrollment in Medicaid or Medicare and resided in a high incidence state as follows: incidence = [(number beneficiaries with Lyme disease algorithm-defined Lyme disease)/(observed person-time at risk for Lyme disease)] × 100,000 person-years.

Main Article

Page created: July 09, 2025
Page updated: August 18, 2025
Page reviewed: August 18, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external